Document is current
Any future updates will be listed below
-
Authors
Simic, Petra
Babitt, Jodie L
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (RO1-DK087727, R01-DK128068, K08DK124568)
Massachusetts General Hospital (Patricia and Scott Eston Massachusetts General Hospital Research Scholar Award)
- License Information
-
More Information
Article History
Accepted: 12 August 2021
First Online: 10 November 2021
Compliance with Ethical Standards
:
: This review article does not present any previously unpublished original research, and ethical approval is therefore not applicable.
: JLB has been a consultant for Incyte Corporation and Alnylam Pharmaceuticals and owns equity in Ferrumax Pharmaceuticals, a company focused on targeting RGM proteins (including hemojuvelin) and bone morphogenetic protein (BMP/TGF-beta) superfamily signaling as hepcidin modulating agents for the treatment of anemia and other iron disorders. Dr. Babitt’s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. PS declares no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
